Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Beneish M-Score: -1.10 (As of Jun. 30, 2026)


NSE:MADHAVBAUG Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
81 GF Score
Price ₹180.60
GF Value ₹216.94
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Vaidyane Ayurved Laboratories Beneish M-Score?

Vaidyane Ayurved Laboratories NSE:MADHAVBAUG +2.96% 81 Beneish M-Score is -1.10 as of Jun. 30, 2026. GuruFocus rates NSE:MADHAVBAUG with a GF Score™ of 81/100 and a GF Value™ of ₹216.94 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 908 Drug Manufacturers companies, Vaidyane Ayurved Laboratories ranks worse than 91.52% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.1 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Vaidyane Ayurved Laboratories's Beneish M-Score or its related term are showing as below:

NSE:MADHAVBAUG' s Beneish M-Score Range Over the Past 10 Years
Min: -3.25   Med: -1.73   Max: 0.01
Current: -1.1

During the past 8 years, the highest Beneish M-Score of Vaidyane Ayurved Laboratories was 0.01. The lowest was -3.25. And the median was -1.73.


Vaidyane Ayurved Laboratories Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Vaidyane Ayurved Laboratories's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaidyane Ayurved Laboratories Beneish M-Score Chart

Vaidyane Ayurved Laboratories Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial 0.01 -1.60 -1.86 -3.25 -1.10

Vaidyane Ayurved Laboratories Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.86 0.00 -3.25 0.00 -1.10

NSE:MADHAVBAUG vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaidyane Ayurved Laboratories Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vaidyane Ayurved Laboratories's Beneish M-Score falls into.


NSE:MADHAVBAUG
81GF Score
Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaidyane Ayurved Laboratories Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vaidyane Ayurved Laboratories for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.9384+0.528 * 0.9574+0.404 * 1.0612+0.892 * 1.1889+0.115 * 0.8001
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.03421-0.327 * 0.8956
=-1.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹176 Mil.
Revenue was ₹1,069 Mil.
Gross Profit was ₹880 Mil.
Total Current Assets was ₹443 Mil.
Total Assets was ₹1,045 Mil.
Property, Plant and Equipment(Net PPE) was ₹241 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹61 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹111 Mil.
Long-Term Debt & Capital Lease Obligation was ₹26 Mil.
Net Income was ₹90 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹54 Mil.
Total Receivables was ₹76 Mil.
Revenue was ₹899 Mil.
Gross Profit was ₹709 Mil.
Total Current Assets was ₹303 Mil.
Total Assets was ₹767 Mil.
Property, Plant and Equipment(Net PPE) was ₹214 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹42 Mil.
Selling, General, & Admin. Expense(SGA) was ₹237 Mil.
Total Current Liabilities was ₹112 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(175.967 / 1069.064) / (76.36 / 899.229)
=0.164599 / 0.084917
=1.9384

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(708.509 / 899.229) / (879.771 / 1069.064)
=0.787907 / 0.822936
=0.9574

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (443.096 + 240.847) / 1045.072) / (1 - (302.847 + 214.459) / 767.094)
=0.345554 / 0.325629
=1.0612

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1069.064 / 899.229
=1.1889

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(41.554 / (41.554 + 214.459)) / (61.295 / (61.295 + 240.847))
=0.162312 / 0.202868
=0.8001

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 1069.064) / (237.241 / 899.229)
=0 / 0.263827
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((25.853 + 111.109) / 1045.072) / ((0 + 112.245) / 767.094)
=0.131055 / 0.146325
=0.8956

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(89.866 - 0 - 54.114) / 1045.072
=0.03421

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vaidyane Ayurved Laboratories has a M-score of -1.10 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.10 mean?
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Beneish M-Score of -1.10 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vaidyane Ayurved Laboratories and its competitors. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #831 out of 908 companies in the Drug Manufacturers industry, placing it in the top 91.5%.
Is Vaidyane Ayurved Laboratories' Beneish M-Score too high?
Vaidyane Ayurved Laboratories' current Beneish M-Score is -1.10. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #831 out of 908 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #831 out of 908 companies for Beneish M-Score. This places Vaidyane Ayurved Laboratories in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vaidyane Ayurved Laboratories and its competitors. Vaidyane Ayurved Laboratories's current Beneish M-Score is -1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹216.94, compared to a current price of ₹180.60 — trading 16.8% below its estimated fair value. The current Beneish M-Score is -1.10. Vaidyane Ayurved Laboratories' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Beneish M-Score is -1.10 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?

Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued. The current stock price of ₹180.60 is trading 16.8% below its estimated GF Value™ of ₹216.94. GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:MADHAVBAUG:

  • Beneish M-Score: -1.10
  • GF Value™: ₹216.94 vs. price of ₹180.60 (16.8% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vaidyane Ayurved Laboratories Business Description

Address 201B, Bhoomi Velocity, Above ICICI Bank, Road No. 23, Wagle Estate, Thane (West), Thane, MH, IND, 400604
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
81GF Score

Get the complete analysis for NSE:MADHAVBAUG

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹180.60
Price
₹216.94
GF Value